The distinct in vivo pharmacokinetic, pharmacodynamic, and immunoregulatory profiles of CAR-T and CAR-NKT cells provide mechanistic insights that help rationalize the design of next-generation cell therapies and combinatorial strategies for solid tumors
An allogeneic FAP-CAR-IL15 iNKT cell therapy depletes FAP+ cancer-associated fibroblasts, enhances the infiltration of T cells, and promotes durable anti-tumour immunity in models of lung tumours and colorectal cancer.
IL-18 co-expression drives broad metabolic reprogramming in CAR-NKT cells including increased oxidative phosphorylation and glycolysis, enhancing their antitumor activity against neuroblastoma
CD38 expression on resting iNKT cells marks an immature subpopulation with diminished type 1 cytokine release, extending the known heterogeneity of the iNKT cell compartment beyond CD4+ and CD4- subsets
iPSC-derived iNKT cells generated via a feeder-free 3D spheroid method produce cytokines with hematopoietic potential and promote myeloid progenitor expansion, suggesting utility as off-the-shelf sources after HSC transplantation
AlloCAR-NKT cells demonstrate superior anti-ovarian cancer efficacy compared to conventional CAR-T cells, with multiple targeting mechanisms, focused tumor homing, and pronounced tumor microenvironment modulation
A protocol for evaluating CAR-NKT cell distribution, persistence, and tumor infiltration in humanized mouse models using in vivo bioluminescence imaging
Glioblastoma-enriched sulfatide lipids activate iNKT cells through CD1d, while lyso-sulfatide inhibits iNKT activation, highlighting sulfatide production as a potential therapeutic target for GBM treatment
A combination of CAR-T and CAR-NKT cells mediated superior therapeutic efficacy against glioma compared to either cell type alone in an immunocompetent mouse model
PRDM1 knockdown in CAR-NKT cells promotes central memory differentiation while preserving effector function, resulting in potent in vivo antitumor activity against neuroblastoma
Single-cell transcriptomics reveal human iNKT cells express naive/precursor, transitional, and Th1/17/NK-like profiles across hematologic tissues, with two distinct CD8+ iNKT expression patterns
Methods for efficiently isolating, genetically modifying, and expanding primary mouse and human iNKT cells using viral vectors for tumor-redirected adoptive cell therapy
A case of lethal hyperleukocytosis in a neuroblastoma patient treated with GD2-CAR.15 NKT cells, with root-cause analysis implicating the use of artificial antigen-presenting cells during manufacturing
The first-in-human clinical trial of “off-the-shelf”, allogeneic CAR-NKTs indicate that these cells are well tolerated and can mediate objective responses in relapsed or refractory NHL and ALL patients even at low doses.
A novel therapeutic strategy utilizing off-the-shelf iNKT cells shows potential for enhancing antitumor immunity in PD-1 refractory tumors and overcoming resistance to checkpoint inhibitors
Donor-specific iNKT biomarkers of survival and sustained functionality, which are conserved in dogs and humans and retained upon CAR-engineering, correlate with extended persistence in immunocompetent, MHC-mismatched canine recipients
Autologous GD2-specific CAR NKT cells co-expressing an interleukin 15 transgene (GD2-CAR.15) exhibited a safe profile in 12 children with neuroblastoma. Two partial responses and one complete response were observed.
CAR-iNKT cells are a powerful anti-tumor therapy, that is further enhanced by combination with checkpoint inhibitors, and can potentially reduce the risk of GVHD after allogeneic hematopoietic stem cell transplantation
Anti-TCRVβ CAR T and CAR iNKT cells show promise for treating T Cell Lymphomas, with CAR iNKTs from healthy donors providing a safe and valuable "off-the-shelf" option